Thus, we verified the supplements’ modulation of the Pparγ, Pparα, and Pparδ genes that actively participate as sensors and regulators of lipid metabolism since they act as therapeutic targets for hypoglycemic agents, such as rosiglitazone, and lipid-lowering agents such as fenofibrate, improving hyperglycemia, insulin resistance, and liver fat accumulation [89]. This evidence concerns the gene PPARG and Hyperglycemia.